{"id":"NCT03362931","sponsor":"Allergan","briefTitle":"Safety and Effectiveness of the XEN45 Glaucoma Treatment System in Patients With Angle Closure Glaucoma","officialTitle":"A Prospective, Multicenter Clinical Trial Designed to Evaluate the Safety and Effectiveness of the XEN45 Glaucoma Treatment System in Patients With Angle Closure Glaucoma","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-07-19","primaryCompletion":"2022-03-18","completion":"2022-03-18","firstPosted":"2017-12-05","resultsPosted":"2023-05-17","lastUpdate":"2023-05-17"},"enrollment":65,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Glaucoma","Angle-Closure"],"interventions":[{"type":"DEVICE","name":"XEN45","otherNames":[]}],"arms":[{"label":"XEN45 Glaucoma Treatment System (hereafter referred to as XEN)","type":"EXPERIMENTAL"}],"summary":"This study will evaluate the safety and IOP-lowering effectiveness of XEN in patients with Angle Closure Glaucoma.","primaryOutcome":{"measure":"Percentage of Participants Achieving at Least a 20% Reduction From Baseline Hour 0 IOP While on the Same Number or Fewer IOP Lowering Medications at Month 12","timeFrame":"Month 12","effectByArm":[{"arm":"XEN45 Glaucoma Treatment System (Hereafter Referred to as XEN)","deltaMin":80.5,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":16,"countries":["Australia","Canada","Singapore","South Korea","Taiwan","United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":12,"n":62},"commonTop":["INTRAOCULAR PRESSURE INCREASED","CONJUNCTIVAL HYPERAEMIA","CONJUNCTIVAL HAEMORRHAGE","CONJUNCTIVAL OEDEMA","VISUAL ACUITY REDUCED"]}}